FDA to shore up legal basis for CRL disclosures as it pauses new releases

The Trump administration is pausing the release of complete response letters for unapproved drugs and moving to create the legal foundation the policy has been missing.

The Office of Management and Budget posted a notice this week indicating that HHS will propose a rule allowing “proactive disclosure of complete response letters.”...